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Evolution of bisphosphonate-related osteonecrosis of the
jaw in patients with multiple myeloma and Waldenstrom’s
macroglobulinemia: a retrospective multicentric study
A Andriani, MT Petrucci, T Caravita, M Montanaro, N Villiva `, A Levi, A Siniscalchi, V Bongarzoni, F Pisani, M De Muro, U Coppetelli,
G Avvisati, A Zullo, A Agrillo and D Gaglioti on behalf of GIMEMA: gruppo laziale MIELOMA MULTIPLO
Bisphosphonates (BPs) are used intravenously to treat cancer-related conditions for the prevention of pathological fractures.
Osteonecrosis of the jaw (BRONJ) is a rare complication reported in 4--15% of patients. We studied, retrospectively, 55 patients
with multiple myeloma or Waldenstrom’s macroglobulinemia followed up from different haematological departments who
developed BRONJ. All patients were treated with BPs for bone lesions and/or fractures. The most common trigger for BRONJ
was dental alveolar surgery. After a median observation of 26 months, no death caused by BRONJ complication was reported.
In all, 51 patients were treated with antibiotic therapy, and in 6 patients, this was performed in association with surgical
debridement of necrotic bone, in 16 with hyperbaric O2 therapy/ozonotherapy and curettage and in 12 with sequestrectomy
and O2/hyperbaric therapy. Complete response was observed in 20 cases, partial response in 21, unchanged in 9 and
worsening in 3. The association of surgical treatment with antibiotic therapy seems to be more effective in eradicating the
necrotic bone than antibiotic treatment alone. O2 hyperbaric/ozonotherapy is a very effective treatment. The cumulative dosage
of BPs is important for the evolution of BRONJ. Because the most common trigger for BRONJ was dental extractions, all
patients, before BP treatment, must achieve an optimal periodontal health.
Blood Cancer Journal (2012) 2, e62; doi:10.1038/bcj.2012.9; published online 23 March 2012
Keywords: bisphosphonate; osteonecrosis; pamidronate; zolendronate; multiple myeloma
INTRODUCTION
Bisphosphonates (BPs) have been mainly used in onco-haematol-
ogy for the treatment of patients with solid tumour and bone
metastasis such as lung, breast and prostate cancer.
1,2 They are
also prescribed for patients with hypercalcaemia, multiple
myeloma (MM), Waldenstrom’s macroglobulinemia (WM), as well
as for osteoporosis and Paget’s disease.
3- -6 Among the different
BPs, the most widely used BPs in oncology and haematology are
pamidronate and zoledronic acid.
7 At the cell level, BPs act by
blocking osteoclast function in several ways: inhibiting the
osteoclast formation from monocytes,
8 reducing osteoclasts’ life
cycle
9 and inhibiting the osteoclastic activity on the bone
surface.
10 At the molecular level, BPs are deemed to modulate
osteoclast function, interacting with a surface cell receptor or with
an intracellular enzyme.
11 Considering that they are not metabo-
lised for long, they are internalized in the osteoclasts, causing their
death (osteoclast apoptosis).
12 In addition to the anti-reabsorption
effect on the bone, an anti-angiogenetic effect on animals has
been recently described.
13 BPs can inhibit the endothelial cell
function both in vivo and in vitro.
14 The cells treated with BPs have
shown a decreased proliferation capability, an increased apoptosis
degree and a reduced capillary vessel formation.
15,16 Other effects
are immunomodulating and antineoplastic.
17,18 As adverse effects,
BP treatment produces ﬂu-like symptoms, fatigue, gastrointestinal
disorders, anaemia, dyspnoea and oedemas.
19 Oral and oesopha-
geal mucosal ulcerations were also observed.
20,21 In 2003,
following the clinical observations by Marx and Stern,
22 a possible
implication of BPs in the development of maxillary osteonecrosis
was postulated. Later, this hypothesis was also supported by
several authors who highlighted a strong correlation between
intra-oral bone necrosis and BP treatment, especially after tooth
avulsion or other oral cavity surgeries.
23- -26 This problem has been
described in neoplastic and non-neoplastic diseases during long-
term treatment with BPs with an incidence between 4 and 15% as
reported in different papers.
24 The most common clinical ﬁnding
is an area of ulcerated mucosa and an exposed devitalized bone.
27
The exposed bone surface is irregular, and the surrounding soft
tissue is often inﬂamed for secondary mucosal infection and is
painful.
28- -30
The treatment objectives for patients with BP-related osteone-
crosis of the jaw (BRONJ) are to eliminate pain, control infection of
the soft and hard tissue, minimize the progression of bone
necrosis and eliminate exposed bone.
19
The aim of this retrospective multicentric study is to describe
the clinical aspects and the evolution of the osteonecrotic lesions
in MM and WM patients treated with BPs and followed up for
more than 6 years.
PATIENTS AND METHODS
We studied retrospectively 55 patients with MM or WM followed up at 10
haematological departments of our region from January 2003 to January
2009. Radiological investigations and biopsies were performed to conﬁrm
clinical diagnosis of BRONJ. Clinical diagnosis was based on the following
criteria: exposed or necrotic bone of maxilla or mandible with or without
pain, evidence of regional soft-tissue inﬂammatory swelling or infection,
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ﬁstula. All patients, but two, were on chemotherapy; none of them was
previously irradiated in the head and neck region or had evidence of MM
bone disease in the jaw. Patients characteristics are summarized in Table 1;
the female/male ratio 42 is noteworthy.
Anatomic localization of the BRONJ was as follows: mandible in 29
patients (52.7%), maxilla in 22 patients (40%) and mandible and maxilla in
4 cases (7.3%). The most common trigger for BRONJ was dental-alveolar
surgery, including extractions (43 patients, 78.4%), dental implant
placement (3 patients, 5.4%), periodontal disease (5 patients, 9%) and
dental prosthesis (3 patients, 5.4%); apparently, only 1 patient (1.8%)
developed BRONJ spontaneously (Table 2). The staging of BRONJ
according to the algorithm described by Ruggiero et al.
19 was as follows:
4/55 patients (7.3%) had stage 1 BRONJ, 46 patients (83.8%) had stage 2
BRONJ and 5 patients (9%) had stage 3 BRONJ. Once BRONJ was
diagnosed, all patients discontinued BP therapy. At the time of diagnosis,
12 patients were in remission of the haematological disease (according to
the classiﬁcation of the International Myeloma working group),
28 whereas
the others were in disease plateau or progression.
According to the clinical BRONJ presentation, patients were treated with
different approaches.
A group of patients received only antibiotic therapy, broad spectrum
or more speciﬁc according to culture antibiogram, in association with
local treatment with benzidamine (that is, quinolone or penicillin plus
metronidazole). A second group received antibiotic therapy in association
with local washes and surgical debridement of necrotic bone. Another
group received antibiotic therapy, O2 hyperbaric/ozonotherapy with or
without surgical debridement and the last group underwent sequestrectomy
(surgical removal of a fragment of dead bone that has separated from
healthy tissue as a result of disease) or partial ostectomy. Ozonotherapy
was performed as described from Petrucci et al.
6 Infact, hyperbaric O2
therapy, by locally increasing the O2 content of the blood, produces a
signiﬁcant reduction in the risk of wound infection.
31
In 19 patients (34.5%), antibiotic therapy was the only treatment used.
Two patients (4%) refused therapy. Six patients (11%) received antibiotic
therapy in association with surgical debridement of necrotic bone. Sixteen
patients (29.%) were treated with antibiotic therapy in combination with
ozonotherapy and surgical debridement; 12 patients (22%) required seques-
trectomy in association with antibiotic and O2/hyperbaric therapy (Table 3).
Statistical analysis
Statistical comparisons among subgroups were carried out using the
Chi-squared test with Yates’ correction for small numbers and Student’s
t-test as appropriate. A stepwise discriminant regression analysis was
performed. The individually tested dependent variables included the
following: cure and amelioration of BRONJ and other clinical data.
Independent variables included sex, site of BRONJ, type of monoclonal
gammopathy, type of BP used and eventually the sequence, total dosage
of BP, type of treatment if medical, surgeon or both, with or without O2
therapy. A cut-off for dosage of zoledronic acid was chosen at a total dose
of 80, 100, 110, 120 and 130mg, considering the distribution of the success
rates at progressive values of these variables. The odds ratio and relative
95% conﬁdence interval were also calculated. Differences were considered
signiﬁcant at a 5% probability level.
RESULTS
After o12 months from the start of the treatment with BPs BRONJ
was observed in 10 patients (18%); after 12--24 months in 16
patients (29%); between 24 and 36 months in 10 patients (18%);
between 36 and 48 months in 4 patients; and after 448 months in
15 patients (Figure 1).
After a median observation time of 28 months (range 4--110
months), no deaths for BRONJ complication were reported. An
intact mucosa was observed in 20 patients (37.75%), 21 patients
(39.6%) still had an intra-oral lesion with improving secondary
infection and pain, the clinical ﬁnding was unchanged in 9
patients (16.3%) and 3 patients (5.4%) developed extra-oral ﬁstula
and fracture due to extensive osteonecrosis with fracture. Two
female patients were not evaluable: one refused any treatment
and the other was lost at follow-up. From our data, we found that
conservative treatment should be used because it can assure a
good quality of life for these patients. Table 4 summarizes the
response type obtained with the different proposed treatment.
From the data, it appears that the combination of atbþcuret-
tage/sequestrectomy is able to obtain a complete resolution of
the BRONJ in 440--60% and 460% patients, respectively.
A statistical analysis performed considering the percentage
of response (resolution, improvement and stabilization/failure)
between the two groups of patient treated with or without O2
Table 1. Characteristics of the population studied
Patients 55
16 Males; 39 females
Median age 72 years (range 56--95)
Immunoglobulin isotype
IgG-k 25 patients
IgG-l 6 patients
IgA-k 12 patients
IgA-l 3 patients
MM-k 3 patients
MM-l 1 patient
WM IgM-k 5 patients
Type of Bisphosphonate used
Pamidronate 1 patient (1.8%)
Zoledronic acid 36 patients (65.5%)
Pamidronate/Zoledronic acid 18 patients (32.7%)
Mean cumulative dose
Pamidronate 2.022mg (range 90- -6.750mg)
Zoledronic acid 84mg (range 4--256mg)
Table 2. Site and trigger of ONJ
SITE of ONJ
Mandible 29 patients (52.7%)
Mandible and maxilla 4 patients (7.3%)
Maxilla 22 patients (40%)
Trigger for ONJ
Dentoalveolar surgery (including
extractions)
43 patients (78.4%)
Dental implant placement 3 patients (5.4%)
Periodontal disease 5 patients (9%)
Dental prothesis 3 patients (5.4%)
No trigger 1 patient (1.8%)
Table 3. Treatment and response
Type of treatment
Antibiotic only 19 patients
Antibiotic+curettage 6 patients
Antibiotic+hyperbaricO2/
Ozonotherapy+curettage 16 patients
Antibiotic+hyperbaricO2/
Ozonotherapy+sequestrectomy 12 patients
No treatment 2 patients
Overall response to treatment
Resolution 20 patients (36.4%)
Improvement 21 patients (38.2%)
No change 9 patients (16%)
Progression 3 patients (0.05%)
Not evaluable 2 patients (3.6%)
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showed a signiﬁcant difference (Po0.007) in favour of the group
treated with O2 therapy/ozonotherapy (Table 5).
Univariate and multivariate analyses were performed to ﬁnd the
different inﬂuence of some factors on the evolution of BRONJ:
type and total dosage of BPs (80, 100, 110, 120 and 130mg of
zoledronic acid), sex and trigger; none of these factors showed a
statistical difference (Table 5). Otherwise, with the Z-test for trend,
between the number of patients who reached a resolution of
BRONJ, we found a statistical difference in the group treated with
low dose of zoledronic acid (Figure 2).
DISCUSSION AND CONCLUSION
BP treatment is generally considered as supportive treatment in
neoplastic disease metastasizing to bone. In a large number of
trials the efﬁcacy of these drugs, as reduction in pathologic
fractures,
19 bone lesions progression has been reported and
advantage in progressive free survival and overall survival
26 is
reported. The complex mechanisms of action of BPs are under
investigation, and not all activities are well known. In our
retrospective analysis, we have selected a homogeneous popula-
tion with MM and WM treated in different haematological
departments. Because of their clinical characteristics, MM patients
are the best candidates to be treated with BPs. However, because
of the prolonged time of BP treatment in MM patients, the BRONJ
has been observed more frequently.
32 Despite this, no prospective
randomized trials have been designed to clearly deﬁne
the etiopathology of this complication. The other in our retro-
spective study, we conﬁrm that the incidence of this complication
is between 4 and 15%, and an important factor for BRONJ is the
cumulative dosage of BPs received. In the majority of the cases,
BRONJ is associated with surgical intervention in the bone of
the jaw. In our study, with the longitudinal clinical follow-up of
28 months (range 4--110 months), we demonstrated that the
majority of the patients reached the remission of the BRONJ with
Table 4. Response to different treatments in 53 patients
a
Total
patients
Resolution Improvement No change/
progression
Antibiotic (Abt) only 19 2 (10.5%) 10 (52.6%) 7 (36.9%)
Abt+Curettage 22 10 (45.5%) 9 (40.9%) 3 (13.6%)
Abt+Sequestrectomy 12 8 (66.6%) 2 (16.7%) 2 (16.7%)
O2 hyperbaric/
ozonotherapy
27 12 (44.4%) 13 (48.2%) 2 (7.4%)
No O2 hyperbaric/
ozonotherapy
26 8 (30.8%) 8 (30.8%) 10 (38.4%)
aTwo pts were not evaluable: one refused treatment and one was lost to
follow-up.
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Figure 1. The number of cases of BRONJ observed during follow-up
(months) after the start of BPs: total number of events 55 cases.
Table 5. Univariate analysis for the following values
Variables Responders Not
responders
P-value
Sex
Males 29 8 0.20
Female 11 5
O2 therapy
Yes 25 2 0.007
Not 16 10
Localization
Superior maxilla 18 4 0.20
Inferior maxilla 20 7
Teeth extration
Yes 28 7 0.20
Not 13 5
Total dosage of bisphosphonate
o80mg 19 5 0.24
480mg 22 7
o100mg 24 5 0.10
4100mg 16 8
o110mg 29 6 0.14
4110mg 12 6
o120mg 34 8 0.10
4120mg 7 4
o130mg 35 8 0.10
4130mg 6 4
Bisphosphonate
Zoledronic acid 26 9 0.20
Zoledronic acid plus
pamidronate
14 3
As considering the percentage of response (resolution, improvement
and stabilization/failure) between the two groups of patient treated
with or without O2therapy/ozonotherapy, there is a signiﬁcance difference
(Po 0.007) in the group treated with O2 therapy/ozonotherapy.
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Figure 2. Probability of resolution or improvement of BRONJ at
different cut-offs of total dosage of zoledronic acid administration
(o80 vs 480mg; o100 vs 4100mg; o110 vs 4110mg; o120 vs
4120mg; and o130 vs 4130mg).
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treatment and sequestrectomy was necessary (12/53 patients). At
the moment, we do not know which is the best treatment for this
complication. In our experience, we ﬁnd that antibiotic treatment
is insufﬁcient to reach a resolution but can obtain exclusively a
containment of the disease; only 10.5% of patients with BRONJ
reached complete response with only antibiotics. If necessary,
debridement and sequestrectomy assure most efﬁcacy (45.5%
and 66.6% of resolution, respectively). In addition, our data show
that O2 hyperbaric/ozonotherapy is very active in the treatment,
because 44.4% of patients obtain complete resolution of BRONJ
in comparison with 30.8% of patients who did not perform this
procedure. In only 7.4% of patients not treated with O2 hyperbaric/
ozonotherapy no change or progression of the lesion was seen.
These data underline the need for the prevention of the BRONJ.
33
It is important to evaluate oral situation before and during BP
treatment. A dental examination with preventive dentistry must
be performed before starting therapy, and some cautions must be
used if dental problems appear during therapy. The use of
antibiotics for germ eradication, the indication to avoid tooth
removal and dental implants and the implementation of non-
surgical control of periodontal disease are universally recognized.
Treatment and time of BP therapy must be decided in single
patients, because only with personalized schedules we can reduce
or avoid this complication. The treatment should be used not
41--2 years. Antibiotic treatment should be used immediately
when the diagnosis is suspected, and conservative surgical
approach must been used if necessary. Although BRONJ is a late
complication of the use of BPs, this complication interferes with
the quality of life of the patients but not on survival, because no
death was observed to be due to infective complications during
prolonging treatment for MM. The use of new guidelines with the
purpose to prevent BRONJ seems to reduce the risk of appearance
of this complication.
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